23 studies found for:    "Porphyria cutanea tarda"
Show Display Options
Rank Status Study
1 Completed Risk Factors of Porphyria Cutanea Tarda (PCT)
Condition: Porphyria Cutanea Tarda
Intervention:
2 Completed
Has Results
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Intervention: Drug: Deferasirox
3 Recruiting Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine;   Procedure: Phlebotomy
4 Unknown  Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Intervention: Drug: Exjade
5 Completed Study of the Pathogenesis of Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Intervention:
6 Recruiting EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Condition: Acute Hepatic Porphyria
Intervention:
7 Completed Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
Condition: Erythropoietic Protoporphyria
Intervention: Drug: cysteine hydrochloride
8 Completed Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Condition: Erythropoietic Protoporphyria
Interventions: Drug: Afamelanotide;   Drug: Placebo
9 Completed Sorbent Therapy of the Cutaneous Porphyrias
Condition: Erythropoietic Protoporphyria
Intervention: Drug: Colestipol
10 Not yet recruiting Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Condition: Acute Intermittent Porphyria
Intervention:
11 Recruiting Longitudinal Study of the Porphyrias
Conditions: Acute Porphyrias;   Cutaneous Porphyrias
Intervention:
12 Active, not recruiting Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Condition: Acute Intermittent Porphyria
Interventions: Genetic: rAAV2/5-PBGD vector dosage 1;   Genetic: rAAV2/5-PBGD vector dosage 2;   Genetic: rAAV2/5-PBGD vector dosage 3;   Genetic: rAAV2/5-PBGD vector dosage 4
13 Unknown  Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
Condition: Erythropoietic Protoporphyria
Intervention: Drug: cysteine hydrochloride
14 Recruiting Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria
Condition: Acute Porphyrias
Interventions: Biological: Panhematin;   Other: Placebo
15 Enrolling by invitation Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria
Conditions: Erythropoietic Protoporphyria (EPP);   X Linked Erythropoietic Protoporphyria
Intervention: Drug: Isoniazid
16 Recruiting Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Conditions: Erythropoietic Protoporphyria;   EPP;   X-Linked Protoporphyria;   XLP;   XLPP;   X-Linked Dominant Erythropoietic Protoporphyria;   XLEPP;   XLDP
Intervention:
17 Completed Porphozym in the Treatment of Acute Attacks in AIP
Condition: Acute Intermittent Porphyria
Intervention: Drug: recombinant human porphobilinogen deaminase (Porphozym)
18 Recruiting Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))
Condition: Erythropoietic Protoporphyria (EPP)
Intervention:
19 Recruiting Clinical Diagnosis of Acute Porphyria
Conditions: Hereditary Coproporphyria (HCP);   Acute Intermittent Porphyria (AIP);   Variegate Porphyria (VP)
Intervention:
20 Active, not recruiting Phase III Confirmatory Study in Erythropoietic Protoporphyria
Condition: Erythropoietic Protoporphyria
Interventions: Drug: Afamelanotide;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
Indicates status has not been verified in more than two years